One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
ArriVent BioPharma, Inc.
AVBP · NGM · Healthcare · Biotechnology
Current price
$19.20
52-week range
$11.36 - $35.83
Market cap
$946.71M
Balance sheet
Healthy
-15.81x Concerning
Net cash $372.77M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -53.3% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 1.5% (peer median: 7.2%).
What this company does
ArriVent BioPharma, Inc.
ArriVent BioPharma develops medicines, mainly for cancer, and is currently testing its main drug, firmonertinib, in clinical trials for lung cancer patients. This matters because if the drug is successful, it could help treat a serious disease. They also have partnerships with other companies to help develop their treatments.
How the company got here
ArriVent BioPharma was founded in 2021 with a mission to find promising cancer medicines developed in other parts of the world and bring them to a global market. The company's strategy is to license these drugs, often those that already show early signs of success in human testing, and then conduct the large-scale clinical trials needed for regulatory approval worldwide. This approach is similar to how its co-founder, Bing Yao, previously helped build and sell another successful biotech company. ArriVent went public in January 2024, raising capital to fund its development efforts.
What it actually does
ArriVent BioPharma is a biotechnology company focused on developing new medicines to treat cancer. As a 'clinical-stage' company, it means their drugs are currently undergoing testing in human trials, rather than being available for patients to use yet. Their main focus is on 'oncology,' which is the study and treatment of cancer. ArriVent identifies potential drug candidates, often licensed from other companies, and then works to get them approved by regulatory bodies like the FDA so they can eventually be prescribed to patients.
Firmonertinib
This is ArriVent's main drug candidate, designed to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC) that has certain genetic mutations, specifically those related to the epidermal growth factor receptor (EGFR). Think of these mutations as specific 'keys' on cancer cells that firmonertinib is designed to block, preventing the cancer from growing. The company is testing firmonertinib in various stages of clinical trials, including a large Phase 3 trial, for patients with different types of EGFR mutations, such as exon 20 insertion mutations and PACC mutations. While firmonertinib has shown promise and received 'Breakthrough Therapy Designation' from the FDA for certain uses, a recent Phase 3 trial (FURVENT) did not meet its primary goal, leading the company to re-evaluate its strategy for this drug. ArriVent has licensed the rights to develop and sell firmonertinib outside of Greater China.
Antibody-Drug Conjugates (ADCs)
ArriVent is also developing a pipeline of drugs known as antibody-drug conjugates, or ADCs. These are innovative treatments that combine the targeting ability of antibodies with the cancer-killing power of chemotherapy drugs. An antibody is like a guided missile that can find and attach to specific targets on cancer cells. Once attached, it delivers a potent chemotherapy 'warhead' directly to the cancer cell, minimizing damage to healthy cells. ArriVent has several ADCs in development, including ARR-217 for gastrointestinal cancers and ARR-002, which targets ovarian and endometrial cancers. These ADC programs represent a diversification of the company's pipeline beyond its lead candidate, firmonertinib.
What management is betting on now
ArriVent's current strategy is to advance its pipeline of cancer therapies, particularly its antibody-drug conjugates (ADCs), while reassessing the path forward for firmonertinib after a recent trial setback. Management is focusing on the development of ARR-217 for gastrointestinal cancers and ARR-002 for ovarian and endometrial cancers, aiming to leverage their potential as targeted therapies. The company also continues to explore firmonertinib's potential in other patient populations, such as those with PACC mutations in lung cancer. ArriVent's financial position, with a significant amount of cash, is expected to support these ongoing development efforts into the future, reducing the immediate need for additional funding.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-49.89M
Diluted EPS
-1.05
Operating cash flow
$-39.58M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-43.32M
Diluted EPS
-0.96
Operating cash flow
$-41.89M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-35.54M
Diluted EPS
-0.69
Operating cash flow
$-30.66M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-34.98M
Diluted EPS
-0.83
Operating cash flow
$-35.80M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-31.40M
Diluted EPS
-0.90
Operating cash flow
$-26.12M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-64.39M
Diluted EPS
-1.90
Operating cash flow
$-68.01M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-20.63M
Diluted EPS
-0.60
Operating cash flow
$-16.15M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-20.56M
Diluted EPS
-0.61
Operating cash flow
$-16.34M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $19.20
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $372.8M - more cash than debt. Interest coverage -15.8x.
Net debt
$-372.77M
Interest coverage
-15.81x
ArriVent BioPharma, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
AVBP
BASELINE
ArriVent BioPharma, Inc.
Total debt $351.00K Interest coverage -15.81x This is the baseline the peer rows are being compared against.
Total debt $754.39M Interest coverage -10.04x Neither company has much profit cushion over interest right now.
Total debt $29.31M Interest coverage -3.49x Neither company has much profit cushion over interest right now.
Total debt $238.00M Interest coverage -48.25x Neither company has much profit cushion over interest right now.
Total debt $37.69M Interest coverage -12.94x Neither company has much profit cushion over interest right now.
What you should know
The case for and against AVBP
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -53.3% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 1.5% (peer median: 7.2%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-5.16x
P/B
2.53x
P/S
—
EV/EBITDA
—
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-53.3%
ROA
-33.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
14.16x
Quick ratio
13.40x
Total debt
$351.00K
Total cash
$373.12M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-3.62
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-147.93M
Free CF TTM
$-160.59M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—